- Deborah brings a wealth of experience from 25+ year career spanning numerous business leadership roles
- Announcement follows recent launch of DXRX – the world's first diagnostic network for precision medicine, enabling industry-wide collaboration to get every patient the treatment they deserve
Belfast/Dublin/Parsippany, December 22, 2020 – Diaceutics PLC, (AIM: DXRX), today announces the appointment of Deborah Davis as Non-Executive Chair, effective from 4 January 2021. Davis brings extensive global experience in software, fintech, telecoms, e-commerce and platform-based businesses.
After completing her undergraduate studies in Australia, Deborah spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay; and technology companies Symantec and Verizon.
She currently holds a number of Non-Executive Director and Board committee positions, including International Personal Finance plc, IDEX Biometrics ASA, Norway, The Institute of Directors UK and Which? Ltd. Her previous Board experience also includes private equity based ieDigital. Deborah is a trustee of the Southern African Conservation Trust.
Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Masters in Science (Management) with Distinction from London Business School.
Deborah will be taking over the role of Non-Executive Chair from Julie Goonewardene who is stepping down following almost 10 years with Diaceutics.
Peter Keeling, Chief Executive Officer of Diaceutics, said: “I am delighted to attract someone of Deborah’s relevant technology background and global experience to join our mission at Diaceutics. With the recent pivotal launch of DXRX – The Diagnostic Network®, we have truly entered a new chapter in the company’s trajectory and I look forward to working with Deborah to capitalise on this.
“We would also like to express our deep gratitude to Julie who has played a key role in Diaceutics becoming the market leader in the development and commercialization of precision medicine diagnostics – helping in our mission to get every patient the treatment they deserve. We are sad to see her go but fully support her in her decision.”
The announcement follows the recent launch of DXRX – The Diagnostic Network®, Diaceutics’ platform designed to facilitate collaboration between pharma, health insurance and government payers, labs and diagnostic companies earlier in the test development process and deliver enhanced coverage and reimbursement support for biomarker testing to improve patient outcomes.
Newly appointed Diaceutics Non-Executive Chair, Deborah Davis.